The Way Forward in Cancer Treatment

The medical approach offers a way to design treatments tailored to the genetic profile of each patient's cancer

- KAVITA BAJELI-DATT @New Delhi

When 69-year-old Arvind (name changed) was diagnosed with advanced small cell lung cancer (SCLC), his prognosis was grim. The disease is aggressive and long-term survival rates are low. Yet three years later, Arvind remains cancer-free, thanks to a combination of chemotherapy and immunotherapy.

"It's a remarkable turnaround," said Dr. Amit Rauthan, professor and head of Medical Oncology, Manipal Hospital, Bengaluru. "We would not have expected such outcomes in advanced SCLC a few years ago. Immunotherapy has truly rewritten the survival narrative for many such patients."

He recalled another case—a young woman with an oncogene-addicted tumor who had failed multiple lines of targeted therapy and developed brain metastases. "She was emotionally and physically drained. We initiated a chemo-immunotherapy combination including Atezolizumab. Not only did the treatment offer clinical benefit, it gave her renewed hope and control," said Dr. Rauthan.

These stories are no longer anomalies but part of a larger trend in precision oncology, a field driven by molecular diagnostics, genomic profiling, and immune checkpoint inhibitors.